Disease Signature and Small vs Big Data in Precision Medicine

This session will review the challenges of operating without an aligned definition of disease signature. We will consider the amount of data we are processing, both small and big data, as well as whether we should be taking advantage of clinical trials to collect as much real-time physical and environmental data.


Mira Marcus-Kalish
Director, International Research Affairs, Tel-Aviv University
Tel Aviv, Israel

Big vs. Small Data Analysis Targeting “Disease Signatures” Towards Precision Healthcare

A 3C- Categorization, Classification & Clustering- strategy, aims to provide a comprehensive insight through a stepwise process, incorporating medical expert knowledge in a structured way into the analysis process of the disease manifestations and potential biomarkers, towards reliable precise medicine.

Two case studies utilizing the 3C strategy, will be presented in this session. A Parkinson’s disease cohort of diagnosed patients and their family members yielding new genotypes associations and the Alzheimer’s disease Neuroimaging Initiative (ADNI) cohort going beyond the discovery of association to new sub-type identification.

To read an interview with Dr. Marcus-Kalish, click here

Yelena Yesha 
Professor, Department of Computer Science and Electrical Engineering, University of Maryland
Baltimore County, USA

A Personalized Approach to Medicine: Utilizing Accelerated Real-Time Analytics for Clinical Data



Ancha Baranova

Associate Professor, School of Systems Biology, George Mason University
Fairfax, USA


Step Away of the Edge of an Illness: Longitudinal Monitoring and Abatement of Stress

Slow Progress of Systemic Inflammation, Insulin Resistance and Metabolic Deficiency serves as the most reliable sign of ageing. These processes directly contribute to pathophysiological course of many chronic diseases. Their hallmarks serve as surrogate biomarkers which could be traced in advance of symptomatic stage. In frame of disease prevention paradigm, when these biomarkers trend away from their optimums, means of the physiological control should be used in longitudinal management of health and as an aid to healthy ageing.

To download the full programme, click here.

Back>>